Rump Alexis, Eder Stefan, Hermann Cornelius, Lamkowski Andreas, Kinoshita Manabu, Yamamoto Tetsuo, Take Junya, Abend Michael, Shinomiya Nariyoshi, Port Matthias
Institut für Radiobiologie der Bundeswehr, München, Germany.
Department of Immunology and Microbiology, National Defense Medical College, Tokorozawa, Japan.
Int J Radiat Biol. 2022;98(5):831-842. doi: 10.1080/09553002.2021.1987570. Epub 2021 Nov 11.
In the case of a nuclear incident, the release of radioiodine must be expected. Radioiodine accumulates in the thyroid and by irradiation enhances the risk of cancer. Large doses of stable (non-radioactive) iodine may inhibit radioiodine accumulation and protect the thyroid ('thyroid blocking'). Protection is based on a competition at the active carrier site in the cellular membrane and an additional temporary inhibition of the organification of iodide (Wolff-Chaikoff effect). Alternatively, other agents like e.g. perchlorate that compete with iodide for the uptake into the thyrocytes may also confer thyroidal protection against radioiodine exposure.Biokinetic models for radioiodine mostly describe exchanges between compartments by first order kinetics. This leads to correct predictions only for low (radio)iodide concentrations. These models are not suited to describe the kinetics of iodine if administered at the dosages recommended for thyroid blocking and moreover does not permit to simulate either the protective competition mechanism at the membrane or the Wolff-Chaikoff effect. Models adapted for this purpose must be used. Such models may use a mathematical relation between the serum iodide concentration and a relative uptake suppression or a dependent rate constant determining total thyroidal radioiodine accumulation. Alternatively, the thyroidal uptake rate constant may be modeled as a function of the total iodine content of the gland relative to a saturation amount. Newer models integrate a carrier-mechanism described by Michalis-Menten kinetics in the membrane and in analogy to enzyme kinetics apply the rate law for monomolecular irreversible enzyme reactions with competing substrates to model the competition mechanism. An additional total iodide uptake block, independent on competition but limited in time, is used to simulate the Wolff-Chaikoff effect.
The selection of the best model depends on the issue to be studied. Most models cannot quantify the relative contributions of the competition mechanism at the membrane and the Wolff-Chaikoff effect. This makes it impossible or exceedingly difficult to simulate prolonged radioiodine exposure and the effect of repetitive administrations of stable iodine. The newer thyroid blocking models with a separate modeling of competition and Wolff-Chaikoff effect allow better quantitative mechanistic insights and offer the possibility to simulate complex radioiodine exposure scenarios and various protective dosage schemes of stable iodine relatively easily. Moreover, they permit to study the protective effects of other competitors at the membrane carrier site, like e.g. perchlorate, and to draw conclusions on their protective efficacy in comparison to stable iodine.
在发生核事故时,预计会释放放射性碘。放射性碘会在甲状腺中蓄积,并通过辐射增加患癌风险。大剂量的稳定(非放射性)碘可抑制放射性碘的蓄积,从而保护甲状腺(“甲状腺阻断”)。这种保护作用基于细胞膜上活性载体位点的竞争以及对碘化物有机化的额外暂时抑制(沃夫-柴可夫效应)。另外,其他物质,如高氯酸盐,可与碘化物竞争进入甲状腺细胞,也可对甲状腺起到保护作用,使其免受放射性碘暴露的影响。放射性碘的生物动力学模型大多通过一级动力学描述各房室之间的交换。这仅在低(放射性)碘化物浓度时能得出正确的预测结果。如果按照甲状腺阻断推荐剂量给药,这些模型并不适合描述碘的动力学,而且也无法模拟细胞膜上的保护性竞争机制或沃夫-柴可夫效应。必须使用为此目的而改编的模型。此类模型可采用血清碘化物浓度与相对摄取抑制之间的数学关系,或采用决定甲状腺总放射性碘蓄积的相关速率常数。或者,甲状腺摄取速率常数可建模为腺体总碘含量相对于饱和量的函数。更新的模型整合了由米氏动力学描述的细胞膜载体机制,并类似于酶动力学,应用具有竞争性底物的单分子不可逆酶反应速率定律来模拟竞争机制。使用一个独立于竞争但时间有限的总碘化物摄取阻断来模拟沃夫-柴可夫效应。
最佳模型的选择取决于要研究的问题。大多数模型无法量化细胞膜上竞争机制和沃夫-柴可夫效应的相对贡献。这使得模拟长时间放射性碘暴露以及稳定碘重复给药的效果变得不可能或极其困难。具有竞争和沃夫-柴可夫效应单独建模的更新的甲状腺阻断模型能够提供更好的定量机制见解,并相对容易地模拟复杂的放射性碘暴露场景和稳定碘的各种保护剂量方案。此外,它们还能研究细胞膜载体位点上其他竞争者(如高氯酸盐)的保护作用,并与稳定碘相比得出其保护效果的结论。